US biotech major Amgen today announced the Phase III FORTITUDE-101 clinical trial evaluating first-line bemarituzumab plus ...

Amgen's Phase 3 trial of bemarituzumab plus chemo met its survival goal in FGFR2b+ gastric cancer, with full data expected ...

Amgen said on Monday its experimental therapy helped patients with advanced gastric cancer live longer when combined with ...

In a detail-thin announcement, Amgen said that adding bemarituzumab to chemotherapy improved overall survival, though ...

Amgen acquired Five Prime in 2021 on the back of the phase 2 FIGHT trial of bemarituzumab, which achieved significant ...

Amgen & Zai Lab's trial shows bemarituzumab + chemo boosts survival in gastric cancer with FGFR2b. Read more here.

THOUSAND OAKS, Calif., June 30, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the Phase 3 FORTITUDE-101 clinical trial evaluating first-line bemarituzumab plus chemotherapy (mFOLFOX6) met ...

Bemarituzumab plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in OS as compared to placebo plus chemotherapy in people living with unresectable ...

Amgen’s investigational monoclonal antibody paired with chemotherapy significantly improved overall survival for patients in ...

“Bemarituzumab is the first FGFR2b inhibitor to demonstrate a statistically and clinically significant overall survival benefit in a randomized Phase 3 trial for the first-line treatment of ...

Bemarituzumab targets FGFR2b, which has been found to be overexpressed in approximately 30% of patients with non-HER2 positive gastric cancer.